Advances in Targeted Protein Degradation in target validation, therapeutics development and translation in the clinic.
The programme brings together world leaders from pharmaceutical and biotechnology companies as well as academic institutions to discuss the latest in Targeted Protein Degradation and PROTAC innovation
Full Registration is now open for Virtual Symposium: Targeted Protein Degradation & PROTAC. Please click the button below to register for this event.
Our LinkedIn group aims to foster discussion and collaboration between experts working in pathology, biomarker development and translational research.
Attendees representing global pharmaceutical organisations, leading biotech companies, internationally renowned academic and healthcare institutions discuss the latest in Targeted Protein Degradation and PROTAC innovation
Day One: 16 February
Day Two: 17 February
The Symposium brings together a panel of prominent leaders, engineers and scientists sharing new case studies, innovative data and industry outlook for the future
CeMM Research Centre for Molecular Medicine
Almac Discovery Ltd
University of California
Amphista Therapeutics Limited
University of Torino
Harvard Medical School
Networking and knowledge Sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of Series features and make the most of participation in a range of virtual, remote experiences.
Syngene is an integrated research, development and manufacturing organisation providing scientific services – from early discovery to commercial supply. We offer services in a wide range of industrial sectors, including pharmaceutical, biotechnology, nutrition, animal health, consumer goods and speciality chemical companies. Our culture of scientific innovation is driven by the expertise of our highly qualified team of 5,000 employees and supported by state-of-the-art infrastructure and market- leading technology.
We offer clients a customised end-to-end solution to fulfil their R&D and manufacturing requirements. This is underpinned by a well-established safety framework, track record of quality and compliance, robust supply chain and access to skilled scientists. Our approach enables us to forge client relationships that move beyond the traditional service outsourcing model into true end-to-end collaborations due to our shared interest in the science and commitment to project delivery.
We recognise that trust is built incrementally project-by-project and we pride ourselves on the many deep, long-term client relationships that underpin our business and demonstrate the value of the work we do.